The Column Group

About The Fund

The Column Group (TCG) is a science-driven venture capital firm that focuses on early-stage investments in the life sciences sector. Founded in 2007 and based in San Francisco, California, TCG is dedicated to building drug discovery companies that have the potential to deliver multiple breakthrough therapeutics. TCG uniquely combines significant financial and operational commitments to support the launch and growth of companies based on innovative scientific platforms. With $600 million in assets under management, they target a range of investment stages, including Early, Seed, Series A, and Series B rounds, with a sweet spot investment of around $1.5 million. Their minimum investment size is $100,000, and they can invest up to $5 million. Throughout its two-decade history, TCG has cultivated unparalleled scientific innovation by funding key advancements in biotechnology. Their success is reflected in generating $4.0 billion in returns and starting and investing in 55 companies, leading to 18 notable company exits. TCG's edge-to-edge investment model encompasses an ecosystem of funds—Platform funds, Opportunity funds, TCG Labs-Soleil, and TCG Crossover (TCGX). These funds operate collaboratively to propel technology platforms, single assets, and later-stage programs from inception through the entire life cycle of opportunity. They take a hands-on approach to guide companies through their development, recruiting top talent, and fostering a culture of scientific excellence and innovation. TCG’s investment strategy is founded on nurturing strong science-driven teams and supporting them even during challenging times, believing in the transformative power of resilient, visionary science. Their team consists of pioneers and visionaries, as well as seasoned partners and venture partners who bring extensive experience in company building and deep understanding of the biotech industry.